Thrivent Financial For Lutherans Sage Therapeutics, Inc. Transaction History

Thrivent Financial For Lutherans

$52.6 Billion
Q3 2024

A detailed history of Thrivent Financial For Lutherans transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 35,749 shares of SAGE stock, worth $195,904. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,749

Previous 35,749 -0.0%

Holding current value

$195,904

Previous $389,000 33.68%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$10.58 - $17.9 $378,224 - $639,907	35,749 New	35,749 $389,000
Q4 2022 Feb 08, 2023	BUY	$32.2 - $43.61 $786,968 - $1.07 Million	24,440 Added 398.89%	30,567 $1.17 Million
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $197,779 - $265,115	6,127 New	6,127 $240,000
Q2 2022 Aug 16, 2022	SELL	$27.52 - $37.99 $168,615 - $232,764	-6,127 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$30.71 - $45.71 $1.26 Million - $1.87 Million	-41,012 Reduced 87.0%	6,127 $203,000
Q4 2021 Feb 16, 2022	BUY	$37.06 - $47.11 $1.75 Million - $2.22 Million	47,139 New	47,139 $2.01 Million
Q2 2021 Aug 19, 2021	SELL	$54.88 - $79.29 $1.09 Million - $1.58 Million	-19,883 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $1.24 Million - $1.71 Million	-17,622 Reduced 46.99%	19,883 $1.49 Million
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $626,213 - $954,812	-10,721 Reduced 22.23%	37,505 $3.24 Million
Q3 2020 Nov 10, 2020	SELL	$41.13 - $62.45 $38,168 - $57,953	-928 Reduced 1.89%	48,226 $2.95 Million
Q2 2020 Aug 12, 2020	BUY	$25.95 - $43.15 $3,399 - $5,652	131 Added 0.27%	49,154 $2.04 Million
Q1 2020 May 15, 2020	SELL	$26.15 - $77.24 $485,239 - $1.43 Million	-18,556 Reduced 27.46%	49,023 $1.41 Million
Q4 2019 Feb 13, 2020	BUY	$60.18 - $154.77 $437,207 - $1.12 Million	7,265 Added 12.05%	67,579 $4.88 Million
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $216,327 - $292,918	1,542 Added 2.62%	60,314 $8.46 Million
Q2 2019 Aug 13, 2019	BUY	$157.85 - $183.09 $52,564 - $60,968	333 Added 0.57%	58,772 $10.8 Million
Q1 2019 May 14, 2019	BUY	$89.33 - $163.65 $51,454 - $94,262	576 Added 1.0%	58,439 $9.3 Million
Q4 2018 Feb 15, 2019	BUY	$81.94 - $139.71 $3.17 Million - $5.41 Million	38,745 Added 202.66%	57,863 $5.54 Million
Q3 2018 Nov 15, 2018	SELL	$138.11 - $169.04 $320,277 - $392,003	-2,319 Reduced 10.82%	19,118 $2.7 Million
Q2 2018 Aug 14, 2018	BUY	$140.36 - $175.76 $16,141 - $20,212	115 Added 0.54%	21,437 $3.36 Million
Q1 2018 May 08, 2018	BUY	$152.15 - $192.33 $41,384 - $52,313	272 Added 1.29%	21,322 $3.43 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $1.28 Million - $3.52 Million	21,050	21,050 $3.47 Million

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.

Account

Thrivent Financial For Lutherans Sage Therapeutics, Inc. Transaction History